Pipeline
OliPass pipelines in clinical and research development
OliPass pipelines in clinical
and research development
OliPass PNA R&D Path
Since the establishment of the company, we have been conducting extensive research on various disease gene targets to identify the pharmacological properties of OliPass PNA. However as the mechanism of action of OliPass PNA has been elucidated as exon skipping, we plan to invest our R&D to build a portfolio of pipelines focusing on clinical development. In addition, we plan to actively collaborate with pharmaceutical companies and biotech companies to develop OliPass PNA Therapeutics from the early stage development and to introduce OliPass PNA into the market.
- SCN9A non-opioid painkiller
- PCSK9 hyperlipidemia
- VEGFA Diabetic Retinopathy
- HIF-1α Solid Tumor
- DMD Duchenne Muscular Disease (Rare Disease)
- PTP1B Type 2 Diabetes
- CTLA4 immuno-oncology
- PD1 immuno-oncology
- NOX4 fibrosis
- "Target X1" Rare Disease (Collaborative R&D)
- "Target X2" Confidential Target (Collaborative R&D)
- Life Style Management (Collaborative R&D with OliPass Cosmeceuticals)
- SCN9A non-opioid painkiller
- PCSK9 hyperlipidemia
- VEGFA Diabetic Retinopathy
- HIF-1α Solid Tumor
- DMD Duchenne Muscular Disease (Rare Disease)
- PTP1B Type 2 Diabetes
- CTLA4 immuno-oncology
- PD1 immuno-oncology
- NOX4 fibrosis
- "Target X1" Rare Disease (Collaborative R&D)
- "Target X2" Confidential Target (Collaborative R&D)
- Life Style Management (Collaborative R&D with OliPass Cosmeceuticals)
OliPass PNA Drug Development Pipeline
Our Pipeline
Research
GLP Safety
Phase 1
Phase 2
Phase 3
NDA
Pain
(SC Injection) SCN9A
(SC Injection) SCN9A
Hyper
cholesterolemia
(Oral) PCSK9
cholesterolemia
(Oral) PCSK9
AMD/DR
(Eye Drop) VEGF
(Eye Drop) VEGF
Chemo/Radio-sensitizer
HIF-1α
DMD
Dystrophin
Type II Diabetes
PTP1B
